Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.

SELARL GRANDE PHARMACIE SAINT JEAN : revenue, balance sheet and financial ratios

SELARL GRANDE PHARMACIE SAINT JEAN is a French company founded 6 years ago, specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé. Based in MELUN (77000), this company of category PME shows in 2024 a net income positive of 113 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-09

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - SELARL GRANDE PHARMACIE SAINT JEAN (SIREN 853195998)
Indicator 2024 2023 2022 2021 2020
Revenue N/C N/C N/C N/C N/C
Net income 112 982 € 110 715 € 116 226 € 174 753 € 46 163 €
EBITDA N/C N/C N/C N/C N/C
Net margin N/C N/C N/C N/C N/C

Revenue and income statement

In 2024, SELARL GRANDE PHARMACIE SAINT JEAN generates positive net income of 113 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2020-2024: 46 k€ -> 113 k€.

Net income (2024) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

112 982 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 228%. Critical situation: debt significantly exceeds equity, severely limiting borrowing capacity and exposing the company to default risk. Financial autonomy (= Equity / Total assets x 100) reaches 26%. The balance between equity and debt is satisfactory.

Debt ratio (2024) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

227.762%

Financial autonomy (2024) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

25.947%

Solvency indicators evolution
SELARL GRANDE PHARMACIE SAINT JEAN

Sector positioning

Debt ratio
227.76 2024
2022
2023
2024
Q1: 16.46
Med: 58.47
Q3: 154.89
Average

In 2024, the debt ratio of SELARL GRANDE PHARMACIE S... (227.76) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.

Financial autonomy
25.95% 2024
2022
2023
2024
Q1: 28.91%
Med: 49.95%
Q3: 69.47%
Watch

In 2024, the financial autonomy of SELARL GRANDE PHARMACIE S... (25.9%) ranks in the bottom 25% of the sector. This ratio represents the share of equity in total financing. Low autonomy may limit investment capacity and increase vulnerability.

Positioning of SELARL GRANDE PHARMACIE SAINT JEAN in its sector

Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé

Valuation estimate

Based on 225 transactions of similar company sales in 2024, the value of SELARL GRANDE PHARMACIE SAINT JEAN is estimated at 1 577 312 € (range 1 098 415€ - 2 359 749€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2024
225 transactions
1098k€ 1577k€ 2359k€
1 577 312 € Range: 1 098 415€ - 2 359 749€
NAF 5 année 2024

Valuation method used

Net Income Multiple
112 982 € × 14.0x = 1 577 312 €
Range: 1 098 415€ - 2 359 749€

Only this financial indicator is available for this company.

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 225 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)

Compare SELARL GRANDE PHARMACIE SAINT JEAN with other companies in the same sector:

Voir toutes les statistiques du secteur Commerce de détail de produits pharmaceutiques en magasin spécialisé

Frequently asked questions about SELARL GRANDE PHARMACIE SAINT JEAN

What is the revenue of SELARL GRANDE PHARMACIE SAINT JEAN ?

The revenue of SELARL GRANDE PHARMACIE SAINT JEAN is not publicly disclosed (confidential accounts filed with INPI).

Is SELARL GRANDE PHARMACIE SAINT JEAN profitable?

Yes, SELARL GRANDE PHARMACIE SAINT JEAN generated a net profit of 113 k€ in 2024.

Where is the headquarters of SELARL GRANDE PHARMACIE SAINT JEAN ?

The headquarters of SELARL GRANDE PHARMACIE SAINT JEAN is located in MELUN (77000), in the department Seine-et-Marne.

Where to find the tax return of SELARL GRANDE PHARMACIE SAINT JEAN ?

The tax return of SELARL GRANDE PHARMACIE SAINT JEAN is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does SELARL GRANDE PHARMACIE SAINT JEAN operate?

SELARL GRANDE PHARMACIE SAINT JEAN operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.